On Sept. 30, 2020, Pfizer and BioNTech announced that preliminary, peer-reviewed data from their ongoing German Phase 1/2 Study of BNT162b1 were published in the journal Nature. BNT162b1 is part of the companiesﾒ mRNA-based vaccine development program Lightspeed against SARS-CoV-2.

The preliminary clinical data from the German study of BNT162b1, a nucleoside-modified messenger RNA (modRNA) candidate that encodes an optimized SARS-CoV-2 receptor binding domain (RBD) antigen, supported and expanded the data from the Phase 1/2 US study.